With Approval Of HeartMate II, Thoratec Aims To Double U.S. Implant Centers
This article was originally published in The Gray Sheet
Executive Summary
Thoratec expects to double the number of U.S. centers implanting the HeartMate II continuous flowventricular assist device from 40 to 80 by the end of 2008
You may also be interested in...
Thoratec Adds Sales Reps For Launch Of HeartMate II As Destination Therapy
Thoratec is beefing up its sales force to emphasize physician referrals now that FDA has approved its HeartMate II ventricular assist device as a "destination" therapy for patients who are not candidates for a heart transplant
Thoratec Adds Sales Reps For Launch Of HeartMate II As Destination Therapy
Thoratec is beefing up its sales force to emphasize physician referrals now that FDA has approved its HeartMate II ventricular assist device as a "destination" therapy for patients who are not candidates for a heart transplant
Thoratec's HeartMate II Implant Boosts Stroke-Free Survival Four-Fold - Study
Thoratec's next-generation HeartMate II continuous-flow left ventricular assist device enables a more than four-fold increase in two-year survival rate free from stroke and reoperation compared with the firm's HeartMate XVE pulsatile-flow LVAD, according to study data unveiled Nov. 17